Medico Remedies Ltd has disclosed regulatory action taken by stock exchanges regarding alleged non-compliance with SEBI Listing Regulations, resulting in penalty payments to both NSE and BSE.

Regulatory Action Details

The pharmaceutical manufacturer received Show of Penalty (SoP) notices from both major Indian stock exchanges on 20th February 2026. The notices pertained to alleged non-compliance with Regulation 6(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Waiver Application Process

Following receipt of the penalty notices, Medico Remedies filed waiver applications with both exchanges on 24th February 2026. However, both applications were subsequently rejected by the respective exchanges.

Company Response and Compliance

The company has paid the requisite SoP fines to both BSE and NSE on 24th February 2026. Management confirmed that from 18th February 2026 onwards, the company is compliant with Regulation 6(1) of the SEBI (LODR) Regulations, 2015.

Impact Assessment

According to the company's disclosure, there is no material impact on financials, operations, or other activities of the company due to this regulatory action. The violation was described as an inadvertent oversight in compliance procedures.

Future Compliance Measures

The company acknowledged that the disclosure was inadvertently missed within prescribed timelines and has committed to ensuring that such unintended failures to disclose within prescribed timelines do not arise in future. This regulatory action serves as a reminder of the importance of strict adherence to listing regulation requirements for publicly traded companies.

Medico Remedies Ltd, a WHO-GMP certified pharmaceutical formulations manufacturer, has informed stock exchanges about receiving Show of Cause (SoP) notices from both NSE and BSE for alleged non-compliance with SEBI listing regulations. The company disclosed this development under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Regulatory Action Details

The pharmaceutical company received SoP notices on 20th February 2026 from both major stock exchanges regarding alleged violations of Regulation 6(1) of the SEBI Listing Regulations. The regulatory action stems from compliance issues identified by the exchanges during their review processes.

Financial Implications

Both exchanges have imposed identical penalties on Medico Remedies Ltd for the alleged regulatory violations. The financial impact of the regulatory action includes specific penalty amounts from each exchange.

Company Response and Actions

Medico Remedies Ltd has taken prompt action in response to the SoP notices received from both exchanges. The company filed waiver applications with NSE and BSE on 24th February 2026, seeking relief from the imposed penalties.

The company has assessed the impact of this regulatory action on its operations and has stated that there is no material impact on its financials, operations, or other activities. This disclosure was made in compliance with SEBI's Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

About the Company

Medico Remedies Ltd is a pharmaceutical formulations manufacturer with WHO-GMP certification, ISO 9001-2015 certification, and recognition as a government-approved Star Export House. The company is headquartered in Mumbai and operates in the pharmaceutical manufacturing sector, focusing on tablet and capsule formulations.